Another benefit of DMARD use in RA. Dr Sood reports lower risk of long term opioid use. Very important given the harm of opioids Abstr#587 #ACR21 @RheumNow https://t.co/d1Dharf5jZ

#ACR21 Abs#0825 Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ) ⭐️Superiority for ABA+MTX and CZP+MTX vs. to csDMARD+GC, not in TCZ+MTX ⭐️ Radiographic progression low in all ▶️ Short study w very aggressive 1st line combo Rx https://t.co/TJPZkqmN8z @Rheumnow

• https://bit.ly/3bO6fSP

Dr Exarchou presents incidence of PsA in Sweden. 22/100000. 75% received DMARDs within 2 years, which seems high, so perhaps this is tip of iceberg with milder cases undiagnosed. Abstr#0571 #ACR21 @RheumNow https://t.co/kANG6KBnOd

For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunogenicity not an issue, is that actually true? Canadian registry data: maybe no after 36m, low no. ?valid, markups mine Need to see more of this! #ACR21 ABST0827 ⁦@RheumNow⁩ https://t.co/VVwd4SZgVx

MTX and liver: FibroScan scores compatible with liver fibrosis are significantly correlated w/ several parameters -BMI -waist circumference -male gender -age but NOT MTX cumulative dose in a cohort of 500+ patients. #Abst0786 @RheumNow #ACR21 https://t.co/RkSpVqN4qF https://t.co/9TENaR0WZ3

• Diagnostic Utility of FibroScan in Screening for Liver Injury in Patients with …

Dr. R Thomas: current studies on prevention of RA: 👉oral DMARDS (MTX, HCQ) 👉biologics (RTX, abatacept) 👉 studies regulating T cells to restore tolerance 👉biomarkers of tolerant state & look at people who don't develop RA 👉 imaging as window of subclin dz. #ACR21 @rheumnow https://t.co/5bsu5459az

#ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX: ▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX. ⭐️Age, sex, waist circumference, BMI are risks @Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7

• https://bit.ly/3bLe4Jb

Blurred line btwn RA, preRA & RA prevention which makes interpretation of RCTs problematic. I’ve learned that if pt has RA not meeting criteria, some Rx ⬇️chance of RA over time-MTX, now #Abatacept but was it RA anyway AND what happens when you stop Rx? #ACR21 @RheumNow abst#0505 https://t.co/HwivsITvCQ

• Aurelie Najm on Twitter: "Provocative study in pre-RA. SC Abatacept in pat…

#ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24% tapered and 14% stopped MTX. No diff in flare rates btw those continued vs tapered/stopped. Sustained remission was in ⬆️tapered vs stopped @RheumNow https://t.co/Mm1yfzRBQz https://t.co/rkHvXWj2oO

• Methotrexate Withdrawal and Outcomes in Participants with Well-controlled Non-s…